SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2024 USD ($) Customer $ / shares	Sep. 30, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($)
Revenue Recognition [Abstract]
Revenues	$ 119,839			$ 67,275			$ 308,905	$ 184,311
Income from operations	39,638			8,685			100,660	7,399
Net income	$ 35,909	$ 32,062	$ 17,806	$ 2,565	$ (6,371)	$ (6,789)	$ 85,777	$ (10,594)
Basic earnings per share (in dollars per share) | $ / shares	$ 0.15			$ 0.01			$ 0.37	$ (0.05)
Diluted earnings per share (in dollars per share) | $ / shares	$ 0.15			$ 0.01			$ 0.35	$ (0.05)
Accrual adjustments	$ 27,535						$ 27,535		$ 32,919
Two Customers [Member] | Revenues [Member] | Customer Concentration Risk [Member]
Revenue Recognition [Abstract]
Number of customers | Customer							2
Percentage of consolidated revenues							71.00%
Accrual for U.S. Medicaid Rebates [Member]
Revenue Recognition [Abstract]
Revenues							$ 12,600
Income from operations							12,600
Net income							$ 11,900
Basic earnings per share (in dollars per share) | $ / shares							$ 0.05
Diluted earnings per share (in dollars per share) | $ / shares							$ 0.05
Accrual adjustments	$ 12,600	$ 12,600					$ 12,600
Biotest License Agreement [Member]
Revenue Recognition [Abstract]
Amortization period							22 years